Oral low-dose tacrolimus therapy for refractory hemophagocytic syndrome associated with systemic lupus erythematosus

References

• Janka GE. Familial and acquired hemophagocytic lymphohistio-cytosis. Eur J Pediatr. 2007;166:95–109.
   PubMed Web of Science ®Google Scholar
• Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6:137–54.
   PubMed Web of Science ®Google Scholar
• Dhote R, Simon J, Papo T, Detoumay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic dis-ease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633–9.
   PubMed Web of Science ®Google Scholar
• Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114:387–90.
   PubMed Web of Science ®Google Scholar
• Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL- lbeta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655–63.
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, airkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–75.
   Google Scholar
• Furukawa Y, Yoshikawa H, Iwasa K, Yamada M. Clinical effi-cacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol. 2008;195:108–15.
   PubMedGoogle Scholar
• Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrol-imus ointment versus vehicle. J Am Acad Dermatol. 2008;58:990–9.
   PubMed Web of Science ®Google Scholar
• Kitahama M, Okamoto H, Koseki Y, Inoue E, Kaneko H, Tan-iguchi A, Momohara S, Yamanaka H. Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. Mod Rheumatol. 2010;20: 478–85.
   Google Scholar
• Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S, Chin HJ. Tacrolimus is an alternative therapeutic option for the treat-ment of refractory lupus nephritis. Lupus. 2010;19:974–80.
   PubMed Web of Science ®Google Scholar
• Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28:6–12.
   PubMed Web of Science ®Google Scholar
• Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage acti-vation syndrome in juvenile arthritis: report of five cases. J Pe-diatr. 1996;129:750–4.
   PubMed Web of Science ®Google Scholar
• Kumakura S, Ishikura H, Kondo M, Murakawa Y, Masuda J, Kobayashi S. Autoimmune-associated hemophagocytic syn-drome. Mod Rheumatol. 2004;14:205–15.
   PubMedGoogle Scholar
• Hide M, Fume M, Ikezawa Z, Shiohara T, Furukawa F, Matsu-naga K, et al. Guidelines for the diagnosis and treatment of urticaria and angioedema. Jpn J Dermatol. 2005;115:703–15.
   Google Scholar
• Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The BILAG-2004 index is sensitive to change for assess-ment of SUE disease activity. Rheumatology (Oxford). 2009;48:691–5.
   PubMed Web of Science ®Google Scholar
• Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocy-tosis: diagnosis, pathophysiology, treatment, and future perspec-tives. Ann Med. 2006;38:20–31.
   PubMed Web of Science ®Google Scholar
• Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford). 2008;47:1686–91.
   PubMed Web of Science ®Google Scholar
• Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating 'Thl and 'Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 1997;89:4100–3.
   PubMed Web of Science ®Google Scholar
• Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest. 1997;100:1969–79.
   Google Scholar
• Kumakura S, Ishikura H, Endo J, Kobayashi S. Autoimmune-associated hemophagocytosis. Am J Hematol. 1995;50:148–9.
   PubMed Web of Science ®Google Scholar
• Quismorio FP, Jr. Hematologic and lymphoid abnormalities in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 801–28.
   Google Scholar
• Kino T, Hatanaka H, Miyata S, et al. FK-506 a novel immuno-suppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40: 1256–65.
   Google Scholar
• Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplan-tation. Drugs. 2003;63:1247–97.
   PubMed Web of Science ®Google Scholar
• Smith DF, Toft DO. Steroid receptors and their associated pro-teins. Mol Endocrinol. 1993;7:4–11.
   PubMed Web of Science ®Google Scholar
• Masri MA. The mosaic of immunosuppressive drugs. Mol Immunol. 2003;39:1073–7.
   PubMed Web of Science ®Google Scholar
• Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46:746–94.
   Google Scholar
• Asamiya Y, Uchida K, Otsubo S, Takei T, Nitta K. Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clin Pract. 2009;113: c330–6.
   Google Scholar
• Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of ta-crolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19:606–15.
   Google Scholar
• Kusunoki Y, Tanaka N, Kaneko K, Yamamoto T, Endo H, Kawai S. Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study. Mod Rheumatol. 2009;19:616–21.
   PubMed Web of Science ®Google Scholar
• Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lym-phocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67:380–8.
   Google Scholar